These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 28049894)

  • 21. Cancer antineovascular therapy with liposome drug delivery systems targeted to BiP/GRP78.
    Katanasaka Y; Ishii T; Asai T; Naitou H; Maeda N; Koizumi F; Miyagawa S; Ohashi N; Oku N
    Int J Cancer; 2010 Dec; 127(11):2685-98. PubMed ID: 20178102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An increased adjuvanticity of liposomes by the inclusion of phosphatidylserine in immunization with surface-coupled liposomal antigen.
    Mori M; Nishida M; Maekawa N; Yamamura H; Tanaka Y; Kasai M; Taneichi M; Uchida T
    Int Arch Allergy Immunol; 2005 Jan; 136(1):83-9. PubMed ID: 15591816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [PEG-liposome in DDS and clinical studies].
    Maruyama K
    Nihon Rinsho; 1998 Mar; 56(3):632-7. PubMed ID: 9549348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Temperature-triggered tumor-specific delivery of anticancer agents by cRGD-conjugated thermosensitive liposomes.
    Kim MS; Lee DW; Park K; Park SJ; Choi EJ; Park ES; Kim HR
    Colloids Surf B Biointerfaces; 2014 Apr; 116():17-25. PubMed ID: 24441178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ligand-targeted liposome design: challenges and fundamental considerations.
    Noble GT; Stefanick JF; Ashley JD; Kiziltepe T; Bilgicer B
    Trends Biotechnol; 2014 Jan; 32(1):32-45. PubMed ID: 24210498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal phagocytic cells.
    Ikehara Y; Shiuchi N; Kabata-Ikehara S; Nakanishi H; Yokoyama N; Takagi H; Nagata T; Koide Y; Kuzushima K; Takahashi T; Tsujimura K; Kojima N
    Cancer Lett; 2008 Feb; 260(1-2):137-45. PubMed ID: 18077084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Colloidal systems for tumor targeting.
    Storm G; Crommelin DJ
    Hybridoma; 1997 Feb; 16(1):119-25. PubMed ID: 9085138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted delivery of transferrin and TAT co-modified liposomes encapsulating both paclitaxel and doxorubicin for melanoma.
    Yuan M; Qiu Y; Zhang L; Gao H; He Q
    Drug Deliv; 2016 May; 23(4):1171-83. PubMed ID: 26036724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Recent development of targeted drug delivery system].
    Zhou PJ; Deng SQ; Gong QF
    Yao Xue Xue Bao; 2010 Mar; 45(3):300-6. PubMed ID: 21351504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoclonal antibody-targeted PEGylated liposome-ICG encapsulating doxorubicin as a potential theranostic agent.
    Lozano N; Al-Ahmady ZS; Beziere NS; Ntziachristos V; Kostarelos K
    Int J Pharm; 2015 Mar; 482(1-2):2-10. PubMed ID: 25445515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhancement of immune responses by DNA vaccination through targeted gene delivery using mannosylated cationic liposome formulations following intravenous administration in mice.
    Hattori Y; Kawakami S; Suzuki S; Yamashita F; Hashida M
    Biochem Biophys Res Commun; 2004 May; 317(4):992-9. PubMed ID: 15094367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes.
    Judge A; McClintock K; Phelps JR; Maclachlan I
    Mol Ther; 2006 Feb; 13(2):328-37. PubMed ID: 16275098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Mitochondrial DDS Opens Innovative Pharmaceutics].
    Yamada Y
    Yakugaku Zasshi; 2016; 136(1):55-62. PubMed ID: 26725668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
    Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
    J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Formation of artificial multicompartment vesosome and dendrosome as prospected drug and gene delivery carriers.
    Paleos CM; Tsiourvas D; Sideratou Z; Pantos A
    J Control Release; 2013 Aug; 170(1):141-52. PubMed ID: 23707326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pluronic F127-modified liposome-containing tacrolimus-cyclodextrin inclusion complexes: improved solubility, cellular uptake and intestinal penetration.
    Zhu Q; Guo T; Xia D; Li X; Zhu C; Li H; Ouyang D; Zhang J; Gan Y
    J Pharm Pharmacol; 2013 Aug; 65(8):1107-17. PubMed ID: 23837579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Implantation of FK506 drug delivery system into the anterior chamber for inhibiting corneal rejection in high risk rabbit corneal allograft].
    Shi WY; Liu T; Xie LX; Wang SG
    Zhonghua Yan Ke Za Zhi; 2006 Apr; 42(4):299-304. PubMed ID: 16762204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-angiogenic nanotherapy via active targeting systems to tumors and adipose tissue vasculature.
    Sakurai Y; Kajimoto K; Harashima H
    Biomater Sci; 2015 Sep; 3(9):1253-65. PubMed ID: 26261854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release.
    Andresen TL; Jensen SS; Jørgensen K
    Prog Lipid Res; 2005 Jan; 44(1):68-97. PubMed ID: 15748655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug delivery strategies in the therapy of inflammatory bowel disease.
    Lautenschläger C; Schmidt C; Fischer D; Stallmach A
    Adv Drug Deliv Rev; 2014 May; 71():58-76. PubMed ID: 24157534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.